Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.

Oncology reports - 1 May 2008

Fujiwara Kazuko, Enomoto Takayuki, Fujita Masami, Kanda Takayoshi, Fujii Shingo, Ito Kimihiko, Wakasa Kenichi, Ishiko Osamu, Ueda Masatsugu, Yamaguchi Satoshi, Kimura Tadashi, Umesaki Naohiko

Abstract excerpt

To better understand the molecular mechanisms of carcinogenesis induced in uterine endometrium by therapeutic anti-estrogenic Tamoxifen (TAM) exposure, 27 uterine tumors (4 benign endometrial polyps and 23 carcinomas) associated with TAM exposure were analyzed for the presence and spectrum of p53 and K-ras mutations. Although there was no significant difference between TAM-associated endometrial carcinomas and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Gene Expression Profiling

Share to Gene Expression Regulation, Neoplastic

Share to Genes, p53

Share to Genes, ras

Share to Tamoxifen

Source

Identifiers

PMID: 18425390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.PMID 18425390Read ↗

Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.Semantic proximity Read ↗

Molecular genetic characterization of tamoxifen-associated endometrial cancer.Semantic proximity Read ↗

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.Semantic proximity Read ↗

Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis.Semantic proximity Read ↗

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene.Semantic proximity Read ↗

K-ras mutation in tamoxifen-related endometrial polyps.Semantic proximity Read ↗

Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.Semantic proximity Read ↗

Rare occurrence of p53 and ras gene mutations in preneoplastic and neoplastic mouse endometrial lesions induced by N-methyl-N-nitrosourea and 17 beta-estradiol.Semantic proximity Read ↗

Molecular basis of endometrial cancerSemantic proximity Read ↗

Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene.Semantic proximity Read ↗

Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations.Semantic proximity Read ↗

Microsatellite instability and somatic mutations in endometrial carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.